文献速递艾滋病与性传播感染

中国男男性行为HIV阳性者快速启动比克替拉韦/恩曲他滨/丙酚替诺福韦复方制剂与依非韦伦/拉米夫定/富马酸替诺福韦二吡呋酯比较:多中心随机临床试验第48周结果

Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV-Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial.
PubMed 文献 · Clin Infect Dis · 2024-01-01

这项多中心、开放标签、随机临床试验在中国HIV阳性男男性行为者中比较快速启动BIC/FTC/TAF与EFV(400 mg)+3TC+TDF的疗效与安全性。第48周BIC组病毒抑制率95.9%高于EFV组79.2%,因不良事件、死亡或失访停药比例BIC组0.7%低于EFV组16.1%,CD4计数增幅BIC组223 cells/μL高于EFV组181 cells/μL,总体不良事件发生率BIC组37.7%低于EFV组65.8%。

要点

  • 第48周病毒抑制率BIC组95.9%高于EFV组79.2%。
  • 因不良事件、死亡或失访停药比例BIC组0.7%低于EFV组16.1%(P < .001)。
  • 总体不良事件发生率BIC组37.7%低于EFV组65.8%(P < .001)。

核心结论

  • 在中国HIV阳性男男性行为者快速启动ART中,BIC/FTC/TAF比EFV(400 mg)+3TC+TDF更有效且更安全。

研究设计与样本

  • 多中心、开放标签、随机临床试验,纳入年龄≥18岁、确诊HIV后14天内启动ART的男男性行为者,按1:1随机分配至EFV(400 mg)+3TC+TDF组或BIC/FTC/TAF组。
  • 2021年3月至2022年7月共纳入300例,EFV组154例,BIC组146例。
  • 主要终点为第48周病毒抑制(<50 copies/mL),采用美国食品药品监督管理局Snapshot分析。

主要发现

  • 第48周EFV组118例(79.2%)与BIC组140例(95.9%)保持 care 且病毒抑制。
  • 因不良事件、死亡或失访停药:EFV组24例(16.1%) vs BIC组1例(0.7%)(P < .001)。
  • 第48周CD4计数中位增幅:EFV组181 cells/μL vs BIC组223 cells/μL(P = .020)。
  • 总体不良事件发生率:EFV组65.8% vs BIC组37.7%(P < .001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most international treatment guidelines recommend rapid initiation of antiretroviral therapy (ART) for people newly diagnosed with human immunodeficiency virus (HIV)-1 infection, but experiences with rapid ART initiation remain limited in China. We aimed to evaluate the efficacy and safety of efavirenz (400 mg) plus lamivudine and tenofovir disoproxil fumarate (EFV + 3TC + TDF) versus coformulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) in rapid ART initiation among men who have sex with men (MSM) who have been diagnosed with HIV. METHODS: This multicenter, open-label, randomized clinical trial enrolled MSM aged ≥18 years to start ART within 14 days of confirmed HIV diagnosis. The participants were randomly assigned in a 1:1 ratio to receive EFV (400 mg) + 3TC + TDF or BIC/FTC/TAF. The primary end point was viral suppression (<50 copies/mL) at 48 weeks per US Food and Drug Administration Snapshot analysis. RESULTS: Between March 2021 and July 2022, 300 participants were enrolled; 154 were assigned to receive EFV + 3TC + TDF (EFV group) and 146 BIC/FTC/TAF (BIC group). At week 48, 118 (79.2%) and 140 (95.9%) participants in the EFV and BIC group, respectively, were retained in care with viral suppression, and 24 (16.1%) and 1 (0.7%) participant in the EFV and BIC group (P < .001), respectively, discontinued treatment because of adverse effects, death, or lost to follow-up. The median increase of CD4 count was 181 and 223 cells/μL (P = .020), respectively, for the EFV and BIC group, at week 48. The overall incidence of adverse effects was significantly higher for the EFV group (65.8% vs 37.7%, P < .001). CONCLUSIONS: BIC/FTC/TAF was more efficacious and safer than EFV (400 mg) + 3TC + TDF for rapid ART initiation among HIV-positive MSM in China.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wang R, Sun L, Wang X, et al. Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV-Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial. Clin Infect Dis. 2024. PMID: 38236137. doi:10.1093/cid/ciae012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。